SGD Pharma introduced My Sterinity Nasal at DCAT Week 2026 in New York, presenting a new ready-to-use (RTU) glass packaging solution for nasal drug delivery.

Developed in collaboration with Prince Sterilization Services, My Sterinity Nasal combines SGD Pharma's Type I U-Save glass vials with specialized sterilization expertise to support the packaging requirements of high-value nasal therapies.

My Sterinity Nasal: Ready-to-Use Glass Packaging for Nasal Therapies

My Sterinity Nasal brings together pharmaceutical glass manufacturing expertise and ready-to-use sterilization capabilities in a solution designed for sensitive nasal drug formulations.

The platform offers several key features:

  • Controlled purity to support pharmaceutical packaging requirements.
  • Biologically inert Type I glass for sensitive formulations.
  • Compatibility with preservative-free nasal pumps.
  • Double-bagged RTU packaging formats to support pharmaceutical manufacturing processes.

These characteristics make the platform relevant to a range of nasal drug delivery applications, from acute to chronic therapies.

A Collaboration with Prince Sterilization Services

The development of My Sterinity Nasal brings together the complementary expertise of SGD Pharma and Prince Sterilization Services.

SGD Pharma contributes its experience in Type I pharmaceutical glass packaging, while Prince Sterilization Services provides RTU sterilization expertise.

Together, the companies aim to offer a validated ready-to-use packaging solution designed to meet the requirements of nasal drug delivery applications.

European Glass Manufacturing and a Regional US Supply Chain

The Type I U-Save glass vials used for My Sterinity Nasal are manufactured at SGD Pharma's Saint-Quentin-Lamotte plant in France, the Group's Type I Center of Excellence.

The solution also benefits from a regional US supply chain, combining European glass manufacturing expertise with supply capabilities serving the North American pharmaceutical market.

This approach supports the development of reliable packaging solutions for sensitive nasal therapies.

Introducing My Sterinity Nasal at DCAT Week 2026

Held in New York from March 23 to 26, 2026, DCAT Week brought together professionals from across the pharmaceutical development and manufacturing industry.

SGD Pharma used the occasion to introduce My Sterinity Nasal and highlight its collaboration with Prince Sterilization Services.

The launch reflects the company's continued commitment to developing pharmaceutical glass packaging solutions that respond to evolving drug delivery requirements.

Discover My Sterinity Nasal and explore how SGD Pharma can support your next nasal drug delivery project.